Big Sky Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2007
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Immunological Intervention in Human Disease (A2)
Organizer(s) Jacques F. Banchereau, Federica Sallusto and Robert L. Coffman
January 6—11, 2007
Big Sky Resort • Big Sky, MT USA
Abstract Deadline: Sep 13, 2006
Late Abstract Deadline: Oct 9, 2006
Scholarship Deadline: Oct 9, 2006
Early Registration Deadline: Nov 6, 2006
Sponsored by the Dana Foundation
Summary of Meeting:
Decades of intense cellular and molecular studies have permitted the identification of many components of the immune system. Studies of the mouse immune system, most particularly through the use of animals with targeted gene inactivation, have permitted remarkable progress in linking these components to specific functions in immunity. In spite of this progress, the study of the human immune system has in general lagged behind that of the mouse. Improvements in technologies, however, now permit a detailed analysis of the altered immune system in human diseases including cancer, allergy, autoimmunity, and infectious diseases. The meeting will emphasize 1) the importance of directly assessing the human immune response and 2) that not all of what we learn in the mouse can be directly translated to humans. To foster interactions between immunologists and pathologists from very different backgrounds, the meeting program includes a wide variety of experts investigating different human diseases that involve alterations of the immune system. Consequently, this meeting is highly likely to contribute to the education of a new generation of immunotherapists.
View Scholarships/Awards
Decades of intense cellular and molecular studies have permitted the identification of many components of the immune system. Studies of the mouse immune system, most particularly through the use of animals with targeted gene inactivation, have permitted remarkable progress in linking these components to specific functions in immunity. In spite of this progress, the study of the human immune system has in general lagged behind that of the mouse. Improvements in technologies, however, now permit a detailed analysis of the altered immune system in human diseases including cancer, allergy, autoimmunity, and infectious diseases. The meeting will emphasize 1) the importance of directly assessing the human immune response and 2) that not all of what we learn in the mouse can be directly translated to humans. To foster interactions between immunologists and pathologists from very different backgrounds, the meeting program includes a wide variety of experts investigating different human diseases that involve alterations of the immune system. Consequently, this meeting is highly likely to contribute to the education of a new generation of immunotherapists.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SATURDAY, JANUARY 6
SUNDAY, JANUARY 7
MONDAY, JANUARY 8
TUESDAY, JANUARY 9
WEDNESDAY, JANUARY 10
THURSDAY, JANUARY 11
Conference Program Print | View meeting in 12 hr (am/pm) time
SATURDAY, JANUARY 6
19:30—20:30
Keynote Session
*
Jacques F. Banchereau,
The Jackson Laboratory for Genomic Medicine, USA
Ralph M. Steinman,
Rockefeller University, USA
Dendritic Cells in Medicine
Dendritic Cells in Medicine
08:00—11:30
Human Immune Effectors and Pathways - I
*
Jacques F. Banchereau,
The Jackson Laboratory for Genomic Medicine, USA
Human Dendritic Cell Subsets
Human Dendritic Cell Subsets
Miriam Merad,
Mount Sinai School of Medicine, USA
Short Talk: Harnessing Tissue Dendritic Cell Homeostasis for the Treatment of Graft Versus Host Disease
Short Talk: Harnessing Tissue Dendritic Cell Homeostasis for the Treatment of Graft Versus Host Disease
Lewis L. Lanier,
University of California, San Francisco, USA
NK Receptors and their Control of Innate Immunity
NK Receptors and their Control of Innate Immunity
Niklas K. Björkström,
Karolinska Institute, Sweden
Short Talk: Fcgamma×RIII+ Effector CD8 T Cells with NK Cell-Like Functions Expand in Response to Chronic Viral Infections
Short Talk: Fcgamma×RIII+ Effector CD8 T Cells with NK Cell-Like Functions Expand in Response to Chronic Viral Infections
Albert S. Bendelac,
University of Chicago, USA
Adjuvant Effects of NKT Ligands
Adjuvant Effects of NKT Ligands
Vicki S. Stronge,
STEMCELL Technologies Inc, Canada
Short Talk: Structural Insights into Glycolipid Loading by CD1d
Short Talk: Structural Insights into Glycolipid Loading by CD1d
Antonio Lanzavecchia,
Institute for Research in Biomedicine, Switzerland
Exploring and Exploiting Human B Cell Memory
Exploring and Exploiting Human B Cell Memory
14:00—16:30
Workshop 1: Assessing Human Immunity
Roshini S. Abraham,
Mayo Clinic, USA
Assessment of Thymic Reconstitution in the Clinical Laboratory Using TRECs as a Marker
Assessment of Thymic Reconstitution in the Clinical Laboratory Using TRECs as a Marker
Florence Allantaz Frager,
Baylor Institute for Immunology Research, USA
Blood Leukocyte Microarray Analysis to Diagnose Systemic Onset Juvenile Idiopathic Arthritis and to follow response to IL-1 Blockade
Blood Leukocyte Microarray Analysis to Diagnose Systemic Onset Juvenile Idiopathic Arthritis and to follow response to IL-1 Blockade
Jonathan C. Choy,
Simon Fraser University, Canada
Induction of iNOS in Bystander Human T Cells Increases Allogeneic Responses in the Vasculature
Induction of iNOS in Bystander Human T Cells Increases Allogeneic Responses in the Vasculature
David R. Karp,
University of Texas Southwestern Medical Center, USA
Analysis of Partial and Complete SLE Phenotypes Using Autoantigen Proteome Arrays
Analysis of Partial and Complete SLE Phenotypes Using Autoantigen Proteome Arrays
Rimpei Morita,
Nippon Medical School, Japan
Follicular Helper T cells: Development and Function
Follicular Helper T cells: Development and Function
Johan K. Sandberg,
Karolinska Institute, Sweden
Impact of HCV/HIV-1 co-infection and Treatment with Pegylated IFNalpha and Ribavirin on NK Cells and the Innate CD1d-Restricted NKT Cells
Impact of HCV/HIV-1 co-infection and Treatment with Pegylated IFNalpha and Ribavirin on NK Cells and the Innate CD1d-Restricted NKT Cells
Blythe D. Sather,
Lyell Immunopharma, USA
Wiskott Aldrich Syndrome Protein is Required for Regulatory T Cell Homeostasis
Wiskott Aldrich Syndrome Protein is Required for Regulatory T Cell Homeostasis
16:45—19:00
Human Immune Effectors and Pathways - II
*
Federica Sallusto,
Università della Svizzera Italiana & ETH Zurich, Switzerland
T Cell Subsets in Disease
T Cell Subsets in Disease
Christine M. Rohowsky-Kochan,
University of Medicine and Dentistry of New Jersey, USA
Short Talk: IL-6 and IL-23 are Critical Factors in the Generation of Human Th17-Secreting T Cells
Short Talk: IL-6 and IL-23 are Critical Factors in the Generation of Human Th17-Secreting T Cells
Rene de Waal Malefyt,
Merck Research Labs, USA
Short Talk: IL-23-Derived Human Th17 Cells Produce IL-17A, IL-17F, IL-22, IL-26, CCL20 and Enhance Epithelial Immunity
Short Talk: IL-23-Derived Human Th17 Cells Produce IL-17A, IL-17F, IL-22, IL-26, CCL20 and Enhance Epithelial Immunity
Yong-Jun Liu,
Sanofi, USA
Plasmacytoid Dendritic Cells
Plasmacytoid Dendritic Cells
Jean-Laurent Casanova,
Rockefeller University, USA
A Genetic Dissection of Cytokine-Mediated Immunity to Infection in Humans
A Genetic Dissection of Cytokine-Mediated Immunity to Infection in Humans
08:00—11:30
Immune Regulation and Autoimmunity - I
*
Jeffrey V. Ravetch,
Rockefeller University, USA
Inhibitory and Stimulatory Fcgamma Receptors
Inhibitory and Stimulatory Fcgamma Receptors
Silvia Gregori,
San Raffaele Telethon Institute for Gene Therapy, Italy
Novel Approaches to Expand/Induce Regulatory T Cells
Novel Approaches to Expand/Induce Regulatory T Cells
Catherine M. Hawrylowicz,
King's College London, UK
Short Talk: TLR9 is Expressed by Human Drug-Induced IL-10 Secreting Treg and Ligation Modulates Function
Short Talk: TLR9 is Expressed by Human Drug-Induced IL-10 Secreting Treg and Ligation Modulates Function
Brian M. J. Foxwell,
Imperial College, UK
A Role for TRL Signaling in Driving Inflammation in RA
A Role for TRL Signaling in Driving Inflammation in RA
Mark Larché,
McMaster University, Canada
Peptide-Based Therapeutic Vaccines for Allergic and Autoimmune Diseases
Peptide-Based Therapeutic Vaccines for Allergic and Autoimmune Diseases
14:00—16:30
Workshop 2: Improving Human Vaccines
David M. Calderhead,
Argos Therapeutics, USA
Development of Superior DC Co-Transfected with RNAs Encoding Antigen and CD40L that Induce Clinically Relevant CD4 Independent CD8 CTL
Development of Superior DC Co-Transfected with RNAs Encoding Antigen and CD40L that Induce Clinically Relevant CD4 Independent CD8 CTL
Mark DeBenedette,
Argos Therapeutics, USA
PME-CD40L DC Prime the Expansion of CD28+/CD45RA- Long Lived Effector Memory CTL Having Clinical Relevance for Dendritic Cell Based Immunotherapies
PME-CD40L DC Prime the Expansion of CD28+/CD45RA- Long Lived Effector Memory CTL Having Clinical Relevance for Dendritic Cell Based Immunotherapies
Albert B. Deisseroth,
Sidney Kimmel Cancer Center, USA
Vector Vaccine for Cancer and Infectious Diseases
Vector Vaccine for Cancer and Infectious Diseases
Larry R. Pease,
Mayo Clinic, USA
Modulation of Immune Polarity and Activation of Antigen-Specific CTL with a Human IgM Antibody that Cross-Links B7-DC
Modulation of Immune Polarity and Activation of Antigen-Specific CTL with a Human IgM Antibody that Cross-Links B7-DC
Georg Stary,
Harvard Medical School, USA
TLR7/8-Activated Inflammatory Denditic CEells as Anti-Cancer Effector Cells
TLR7/8-Activated Inflammatory Denditic CEells as Anti-Cancer Effector Cells
Chun I. Yu,
Baylor Research Institute, USA
Humice to test efficacy of vaccines against Influenza virus
Humice to test efficacy of vaccines against Influenza virus
*
Robert A. Seder,
NIAID, National Institutes of Health, USA
TLR Ligands Influence the Quality of T Cell Responses
TLR Ligands Influence the Quality of T Cell Responses
17:00—19:00
Immune Regulation and Autoimmunity - II
Jürg Tschopp,
University of Lausanne, Switzerland
The Inflammasome: A Danger Signal Sensing Complex Involved in Autoinflammatory Diseases
The Inflammasome: A Danger Signal Sensing Complex Involved in Autoinflammatory Diseases
*
Virginia Pascual,
Cornell University, USA
IFNa and IL1 in Human Autoimmunity
IFNa and IL1 in Human Autoimmunity
Michel Gilliet,
University Hospital of Lausanne, Switzerland
Short Talk: Innate Activation of Plasmacytoid DC by an Endogenous Peptide
Short Talk: Innate Activation of Plasmacytoid DC by an Endogenous Peptide
08:00—11:15
Innovations in Cancer I
Louis M. Staudt,
NCI, National Institutes of Health, USA
Gene Expression Signatures of the Immune Response to Guide the Diagnosis, Prognosis and Treatment of Cancer
Gene Expression Signatures of the Immune Response to Guide the Diagnosis, Prognosis and Treatment of Cancer
Andrew C. Chan,
Genentech, Inc., USA
Targeting B Cells in Cancer and Autoimmunity
Targeting B Cells in Cancer and Autoimmunity
Bretton C. Summers,
Genentech, USA
Short Talk: CXCR7 (RDC1) Directly Regulates Breast and Lung Cancer
Short Talk: CXCR7 (RDC1) Directly Regulates Breast and Lung Cancer
*
Laurence Zitvogel,
Institut Gustave Roussy, France
Molecular Determinants of the Immunogenicity of Cell Death: Designing Tumor Vaccines with Apoptosis Inducers
Molecular Determinants of the Immunogenicity of Cell Death: Designing Tumor Vaccines with Apoptosis Inducers
Hideki Ueno,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Circulating Tumor-Associated Antigen Specific Regulatory CD4+ T Cells in Patients with Metastatic Melanoma
Short Talk: Circulating Tumor-Associated Antigen Specific Regulatory CD4+ T Cells in Patients with Metastatic Melanoma
Philip D. Greenberg,
University of Washington, USA
Adoptive T Cell Therapy of Cancer and Viral Diseases
Adoptive T Cell Therapy of Cancer and Viral Diseases
16:45—19:00
Innovations in Cancer II
*
Olivera J. Finn,
University of Pittsburgh School of Medicine, USA
Targeting MUC1 to Prevent Cancer
Targeting MUC1 to Prevent Cancer
Dean L. Mann,
University of Maryland Medical School, USA
Short Talk: Studies on the Safety of Intra-Tumoral Injuction of Autologous Dendritic Cell and Activated T Cells Combined With Conventional Therapies in Patients with Advanced Cancers
Short Talk: Studies on the Safety of Intra-Tumoral Injuction of Autologous Dendritic Cell and Activated T Cells Combined With Conventional Therapies in Patients with Advanced Cancers
Madhav V. Dhodapkar,
Yale School of Medicine, USA
Probing Immune Response to Human Premalignancy
Probing Immune Response to Human Premalignancy
08:00—11:00
Innovations in Human Infections
*
Richard A. Koup,
NIAID, National Institutes of Health, USA
Prime-Boost Vaccination Against HIV Infection
Prime-Boost Vaccination Against HIV Infection
Rafick Sekaly,
Emory University, USA
Reconstituting the HIV Specific Immune Response
Reconstituting the HIV Specific Immune Response
Erika Adriana Eksioglu,
H. Lee Moffitt Cancer Center, USA
Short Talk: Dendritic Cell Response to Hepatitis C Virus
Short Talk: Dendritic Cell Response to Hepatitis C Virus
Susanne I. S. Nylén-Spoomaker,
NIAID, National Institutes of Health, USA
Short Talk: Human Visceral Leishmaniasis is Associated with IL-10 Producing T Cells that are Distinct from CD4+CD25+ (Foxp3) Regulatory T Cells
Short Talk: Human Visceral Leishmaniasis is Associated with IL-10 Producing T Cells that are Distinct from CD4+CD25+ (Foxp3) Regulatory T Cells
14:00—16:30
Workshop 3: Improving Autoimmunity and Allergy
*
Robert L. Coffman,
Dynavax Technologies, USA
Development of TLR7/9 Antaganoists for SLE
Development of TLR7/9 Antaganoists for SLE
Ilan Bank,
Tel Aviv University, Israel
alpha1beta1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNFalpha Blockade
alpha1beta1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNFalpha Blockade
Alma-Martina Cepika,
Stanford School of Medicine, USA
Toll-Like Receptors and Regulatory T Cells in Systemic Lupus Erythematosus
Toll-Like Receptors and Regulatory T Cells in Systemic Lupus Erythematosus
Grayson B. Lipford,
Janus Biotherapeutics, Inc., USA
A Selective Toll-like Receptor 7/8/9 Antagonist for the Oral Treatment of Systemic Lupus Erythematosus
A Selective Toll-like Receptor 7/8/9 Antagonist for the Oral Treatment of Systemic Lupus Erythematosus
Nicola M. G. Smith,
University of Oxford, UK
Defining an Effector T Cell Population in a Surrogate Model for RA
Defining an Effector T Cell Population in a Surrogate Model for RA
Horst von Bernuth,
University V René Descartes, France
Human MyD88 Deficiency : A Novel Primary Immunodeficiency
Human MyD88 Deficiency : A Novel Primary Immunodeficiency
Matthew J. Walters,
ChemoCentryx, USA
Pharmacological Inhibition of Gut Homing CCR9 T-cells Alters Disease Severity in Murine Models of Inflammatory Bowel Disease
Pharmacological Inhibition of Gut Homing CCR9 T-cells Alters Disease Severity in Murine Models of Inflammatory Bowel Disease
Kazuyuki Yoshizaki,
Osaka University, Japan
Immunological Intervention in Rheumatoid Arthritis by the Blocking of Interleukin 6 a Single Cytokine
Immunological Intervention in Rheumatoid Arthritis by the Blocking of Interleukin 6 a Single Cytokine
Chunfeng Qu,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences, China
Maturation and Cross-Presentation by Human Monocyte-Derived Cells After Uptake of Apoptotic Flu-Infected or Poly-IC-Loaded Autologous Cells
Maturation and Cross-Presentation by Human Monocyte-Derived Cells After Uptake of Apoptotic Flu-Infected or Poly-IC-Loaded Autologous Cells
16:45—19:30
Humanized Mouse Models
*
A. Karolina Palucka,
The Jackson Laboratory for Genomic Medicine, USA
Understanding the Interplay of the Human Immune System with Cancer in Immunodeficient Mice
Understanding the Interplay of the Human Immune System with Cancer in Immunodeficient Mice
Sean M. Stevens,
Regeneron Pharmaceuticals Inc., USA
VelocImmune: Mice with Genetically Humanized Immune Systems, Constructed via VelociGene Technology
VelocImmune: Mice with Genetically Humanized Immune Systems, Constructed via VelociGene Technology
Markus G. Manz,
University Hospital Zürich, Switzerland
Human Adaptive Immune System Rag2-/-gammac-/-Mice: Opportunities and Limitations
Human Adaptive Immune System Rag2-/-gammac-/-Mice: Opportunities and Limitations
Frank Oliver Nestle,
Sanofi, USA
Short Talk: Insights From a Humanized Mouse Model of Psoriasis Define a Novel Epithelial Homing Effector T Cell Population
Short Talk: Insights From a Humanized Mouse Model of Psoriasis Define a Novel Epithelial Homing Effector T Cell Population
Hergen Spits,
University of Amsterdam, Netherlands
Construction of Human Immune System in Mice
Construction of Human Immune System in Mice
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
